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ABSTRACT
Despite the importance of UDP-glucuronosyltransferase (UGT)
1A1*28 in irinotecan pharmacogenetics, our capability to predict
drug-induced severe toxicity remains limited. We aimed at
identifying novel genetic markers that would improve prediction
of irinotecan toxicity and response in advanced colorectal
cancer patients treated with folic acid (leucovorin), fluorouracil
(5-FU), and irinotecan (camptosar)-based regimens. The rela-
tionships between UGT1A candidate markers across the gene
(n 5 21) and toxicity were prospectively evaluated in 167
patients. We included variants in the 39untranscribed region
(39UTR) of the UGT1A locus, not studied in this context yet.
These genetic markers were further investigated in 250 Italian
FOLFIRI-treated patients. Several functional UGT1A variants,
including UGT1A1*28, significantly influenced risk of severe
hematologic toxicity. As previously reported in the Italian cohort,
a 5-marker risk haplotype [haplotype II (HII); UGTs 1A9/1A7/1A1]
was associated with severe neutropenia in our cohort [odds ratio
(OR) 5 2.43; P 5 0.004]. The inclusion of a 39UTR single-
nucleotide polymorphism (SNP) permitted refinement of the
previously defined HI, in which HIa was associated with the
absence of severe neutropenia in combined cohorts (OR5 0.55;
P 5 0.038). Among all tested UGT1A variations and upon
multivariate analyses, no UGT1A1 SNPs remained significant,
whereas three SNPs located in the central region ofUGT1Awere
linked to neutropenia grade 3–4. Haplotype analyses of these
markers with the 39UTR SNP allowed the identification of
a protective HI (OR 5 0.50; P 5 0.048) and two risk haplotypes,
HII and HIII, characterized by 2 and 3 unfavorable alleles,
respectively, revealing a dosage effect (ORs of 2.15 and 5.28;
P # 0.030). Our results suggest that specific SNPs in UGT1A,
other than UGT1A1*28, may influence irinotecan toxicity and
should be considered to refine pharmacogenetic testing.
Introduction
Irinotecan (Camptosar, CPT-11), a topoisomerase I in-
hibitor, is a standard cytotoxic agent used for the treatment of
advanced metastatic colorectal cancer. Despite its clinical
efficacy, irinotecan has two major dose-limiting toxicities—
myelosuppression and diarrhea—that occur with unpredictable
severity (Saltz et al., 2000; Rothenberg et al., 2001).
Irinotecan has a narrow therapeutic range, and adverse
effects may limit the dose that can be safely administered,
and subsequently compromise tumor response and clinical
outcome. A greater knowledge of human genetic variations
pertaining to these variable outcomes following irinotecan
treatment may allow an individualized approach to therapy.
The interindividual variability of irinotecan dose/toxicity
and tumor response has been attributed mainly to inherited
genetic variations in the UGT1A1 gene, which encodes UDP-
glucuronosyltransferase (UGT) 1A1, a key enzyme in irinotecan
metabolism. The human UGT1A locus is defined by 13 first
exons, which are alternatively spliced to four common exons,
leading tomRNA isoforms, nine of which conduct to functionally
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active enzymes. Indeed, following intravenous administra-
tion, irinotecan is converted in vivo to the highly potent
active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) by
carboxylesterase-mediated hydrolysis (Kawato et al., 1991;
Kojima et al., 1993). SN-38 is conjugated with glucuronic acid
by hepatic and extrahepatic UGTs to form inactive SN-38-
glucuronide. Several studies have identified specific inherited
differences in irinotecan glucuronidation capacity that in-
fluence toxicity (Ando et al., 2000; Iyer et al., 2002; Innocenti
et al., 2004; Marcuello et al., 2004; Mathijssen et al., 2004;
Carlini et al., 2005; de Jong et al., 2006; McLeod et al., 2006;
Toffoli et al., 2006). An increased number of dinucleotide
repeats in the atypical TATA-box region of the UGT1A1
promoter (UGT1A1*28 allele) leads to a decreased rate of
transcription initiation/expression of UGT1A1 (Beutler et al.,
1998). Several studies suggest that patients homozygous for
UGT1A1*28 are more likely to develop dose-dependent severe
neutropenia compared with individuals with the reference
genotype (*1/*1) (Iyer et al., 2002; Innocenti et al., 2004;
Marcuello et al., 2004; Carlini et al., 2005; Soepenberg et al.,
2005; Toffoli et al., 2006; Hoskins et al., 2007). Other genetic
variations also linked to toxicity, such as the nonsynonymous
coding variant G71R (UGT1A1*6 allele), are particularly
prevalent in Asians (frequency of 0.13–0.25), and lead to
variable enzyme activity (Jada et al., 2007). Additionally,
there are few data regarding the relationship with diarrhea,
the other major adverse effect (Carlini et al., 2005; Toffoli
et al., 2006). Thus, the clinical value ofUGT1A1 polymorphisms
as predictors of irinotecan-associated toxicity has limitations,
supporting the need for additional studies before implementa-
tion of individualized irinotecan dosing.
Along with UGT1A1 enzyme, several studies have revealed
the importance of UGT1A9 in the hepatic conjugation of
SN-38, whereas UGT1A7 is predominantly involved in its
extrahepatic metabolism (Hanioka et al., 2001; Gagne et al.,
2002). UGT1A6 has catalytic activity toward SN-38 in vitro
(Gagne et al., 2002), but the effect on irinotecan metabolism is
relatively undefined in vivo. Recent observations suggest that
a combined signature of the haplotypes ofUGT1A1, UGT1A6,
UGT1A7, and UGT1A9 might provide more precise informa-
tion about irinotecan pharmacokinetics, pharmacodynamics,
and time to progression defined as the interval between the
first drug [FOLFIRI; folic acid (leucovorin; Pfizer, Saint-
Laurent, QC, Canada), fluorouracil (5-FU; Hospira, Montreal,
QC, Canada), and irinotecan (camptosar; Pfizer)] administra-
tion and the date of first disease progression (documented by
computed tomography scans of measurable lesions) or last
follow-up (Cecchin et al., 2009). Therefore, clinical outcome is
likely the result of complex interplay, at least in part, between
key genomic variations in UGT metabolic detoxification
pathways.
Here, a cohort of 167 Canadian patients treated with
FOLFIRI-based regimens for metastatic colorectal cancer was
prospectively studied for hematologic and gastrointestinal
(GI) toxicities in relation to germline polymorphisms in the
major UGT1A gene. A first series of analyses focused on
specific UGT1A variants, including the UGT1A1*28, and
their haplotypes that were previously associated with severe
neutropenia by Cecchin et al. (2009) in an Italian cohort of 250
patients also treated with FOLFIRI. We replicated the idea
that a haplotype II [HII; single-nucleotide polymorphisms
(SNPs) inUGT1As 1A9/1A7/1A1) is associated with increased
risk of neutropenia, as reported in the Italian cohort (Cecchin
et al., 2009). We also tested the inclusion of a 39untranscribed
region (39UTR) variant common to all UGT1As, and defined
a novel haplotype associated with the absence of neutropenia
(HIa) in the combined analysis of Canadian and Italian pa-
tients. In a second series of investigations, we tested a broader
range of variations across theUGT1A gene (n5 21) genotyped
in Canadian patients, with the aim to identify a better com-
bination of UGT1A markers (haplotypes) associated with the
presence and absence of neutropenia. We report 4-marker hap-
lotypes (SNPs in UGTs 1A9/1A7/1A6/39UTR) that may help to
refine prediction of hematologic toxicities, and ultimately im-
prove dosing strategies.
Materials and Methods
Study Design and Patients
This multi-institution prospective study involved patient re-
cruitment from 2003 to 2012 at three medical centers in eastern
Canada: Hotel-Dieu de Québec in Québec City, QC; Hotel-Dieu de
Lévis in Lévis, QC; and The Ottawa Hospital in Ottawa, ON. The
ethics committee of each participating institution approved the
study protocol, and all patients signed a written informed consent
before entering the study. Eligibility criteria included patients
(18–90 years old) initiating their first irinotecan-based chemother-
apy with a histologically confirmed metastatic colorectal cancer,
a life expectancy of at least 3 months, and a good performance status
(Eastern Cooperative Oncology Group # 2). Table 1 summarizes
patient characteristics, such as age, gender, tumor site, treatment,
and toxicity. The primary objective was to assess the relationship
between SNPs in candidate genes and irinotecan-induced toxicity.
The second cohort is composed of 250 metastatic cases and was
previously described elsewhere (Toffoli et al., 2006; Cecchin et al.,
2009).
Treatments
Patients were treated with one of the following FOLFIRI-based
chemotherapies. Patients treated with the modified FOLFIRI re-
gimen received irinotecan (180 mg/m2 i.v.) for 2 hours on day 1 plus
a bolus of 5-fluorouracil (400 mg/m2) followed by continuous infusion
of 5-fluorouracil (2400 mg/m2) plus leucovorin (200 mg/m2) over 46
hours. Patients received this treatment cycle every two weeks. Sixty-
nine patients also received the monoclonal antibody bevacizumab
(Avastin; Genentech, San Francisco, CA) in coadministration with
their regimen, and 6 patients received either an experimental drug
or placebo.
TABLE 1















Diarrhea (grade 3-4) 24 14.4
Neutropenia (grade 3-4) 28 16.8
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Efficacy Assessment. Computed tomography scans of measur-
able lesions were recorded prior to irinotecan chemotherapy and every
four to eight doses after the start of treatment. Objective response and
duration of response were assessed by Response Evaluation Criteria
in Solid Tumors. Patients were considered evaluable for response if
they had at least four doses of chemotherapy.
Toxicity Assessment. Toxicity was evaluated prospectively and
according to National Cancer Institute Common Terminology Criteria
for Adverse Events version 3.0 criteria. The toxicity endpoints
consisted of both GI and hematologic toxicities, and were analyzed
separately. For GI toxicities, all patients completed a daily report of
GI toxicities during the first 14 days of each cycle to record the
incidence and severity of nausea, vomiting, and diarrhea. For
hematologic toxicities, laboratory parameters were collected before
each cycle of chemotherapy and/or when the treatment was delayed.
The most severe toxicity reported was used for data analysis. GI
toxicity was evaluable for all patients except for one who died before
toxicity assessment, and another who did not fill out the GI toxicity
diary, while hematologic toxicity was evaluable for 166 of 167
patients. For the Italian cohort, details on eligibility, modalities of
treatment, data collection, and definitions have been published
previously (Toffoli et al., 2006; Cecchin et al., 2009).
Genotyping
Polymorphisms included in this study and their amplification
strategies including primer sequences are described in the supple-
mentary materials (Supplemental Tables 1 and 2). Variations linked
at r2 $ 0.95 with another variant included or determined to be
relatively rare [minor allele frequency (MAF) of ,0.5%] were omitted
in further analyses. At the time of patient enrollment, genomic DNA
was obtained from a blood sample using a genomic DNA extraction kit
(QIAampDNABloodMini kit; Qiagen,Mississauga, ON, Canada).We
identified polymorphisms by sequencing polymerase chain reaction
products using an ABI PRISM 3730XL DNA Analyzer (Applied
Biosystems, Foster City, CA). All polymerase chain reactions were
carried out in a final volume of 50 ml, containing 30 ng of genomic
DNA, 3mMMgCl2, 200 nM of each deoxynucleotide triphosphate, 300
nM of each primer, 5% acetamide, and 1 U Taq polymerase. Each
reaction was incubated at 94°C for 30 seconds followed by 35 cycles at
94°C for 30 seconds, 55–58°C for 30 seconds, and 72°C for 30 minutes,
with a final step at 72°C for 5 minutes. All sequences were analyzed
with the Staden package (Open Source Technology Group, Fairfax,
VA; http://staden.sourceforge.net/) and compared with the reference
sequence to assess genetic variations. Samples given an ambiguous
sequencing chromatogram were systematically reamplified and rese-
quenced. Genotyping was performed independently without knowledge
of the clinical evaluations.
Data Analyses and Statistics
Deviations from the Hardy-Weinberg equilibrium of allele and
genotype frequencies for the various genetic variations were assessed
by Fisher’s exact test. Haplotypes were inferred using the Phase
version 2.1.1 program (Stephens et al., 2001; Stephens and Donnelly,
2003). Pairwise linkage disequilibrium (LD) was determined with
HAPLOVIEW 3.32 (www.broad.mit.edu/mpg/haploview). Pairwise
LD between polymorphisms was estimated by a log-linear model,
and the extent of disequilibriumwas expressed in terms of D’, which is
the ratio of the unstandardized coefficient to its maximal/minimal
value. The possibility of genetic association was examined by testing
the null hypothesis using two-tailed Fisher’s exact test, and was
considered statistically significant at P # 0.05 as calculated by
JMP4.0.2 software (JMP Statistical Discovery, Cary, NC) or the SAS
statistics package (SAS Institute, Cary, NC). When a particular
variant was infrequent in the studied cohort (n# 3), homozygous and
heterozygous genotypes were combined for statistical analyses.
Genetic variants deemed positive (P , 0.05) or with a trend (P ,
0.10) by univariate analysis were included in a stepwise logistic
regression analysis. No adjustments were made for multiple compar-
isons because of the exploratory nature of this study.
Results
Patient characteristics for the Canadian cohort are sum-
marized in Table 1. Rates of grade 3–4 hematologic and GI
toxicities prospectively evaluated were in keeping with pre-
vious reports (Schulz et al., 2009) (Supplemental Table 3). We
studied 21 SNPs of the UGT1A gene genotyped in the cohort
of 167 Canadian patients in relation to hematologic and GI-
related toxicities. The observed allele frequency for selected
SNPs was in agreement with previous analyses, and all of the
SNP markers under study are in Hardy-Weinberg equilib-
rium, except for rs10929302 (P5 0.01) (Supplemental Table 2)
(Maitland et al., 2006; Thomas et al., 2006; Menard et al.,
2009). Pairwise LD analysis was performed with variations
having a MAF . 0.05. As expected, the high LD observed for
UGT1A variants agreed with data from a recent published
analysis of a population from the same geographic region
(Menard et al., 2009).
We initially tested previously reported haplotypes of the
UGT1A locus named according to Cecchin et al. (2009) to
thereby allow comparison between studies and avoid nomen-
clature confusion. Four haplotypes were inferred by 5 markers
and occurred at a frequency of $5% in the Canadian cohort.
We observed that haplotype HII, characterized by the co-
occurrence of SNP susceptibility alleles includingUGT1A1*28,
is associated with a higher risk of severe neutropenia [odds
ratio (OR) 5 2.43; P 5 0.004], as reported by Cecchin et al.
(2009) for the Italian cohort (Fig. 1). The inclusion of an
additional UGT1A-associated SNP located in the 39UTR
region resulted in two HI-related haplotype alleles, called
HIa and HIb. Whereas the HIb is evenly distributed between
patients who have or have not experienced neutropenia, the
HIa allele is largely associated with severe neutropenia in
both the Canadian and Italian cohorts (n 5 417; OR 5 0.55;
P 5 0.038).
In a second series of analyses, we included 21 variations
across the UGT1A gene genotyped in the Canadian cohort.
In univariate analyses of the Canadian cohort, UGT1A
variants were linked to severe neutropenia but not GI
toxicities (unpublished data). Severe neutropenia was as-
sociated with numerous variants with a MAF . 5% at the
UGT1A locus (P , 0.05), including functional coding
variants of UGT1A6 and UGT1A7; three promoter poly-
morphisms of UGT1A9 [c.-1212 (G/A), c.-688 (A/C), and
c.-440 (C/T)], the common promoter UGT1A1*28 (c.-54_-53
TA6/7) allele; and promoter variant c.-3156 (G/A), most of
which are known to impair gene expression or function
(Bosma et al., 1995; Beutler et al., 1998). ORs and P values
for association with hematologic toxicities are indicated in
Table 2. For instance, the UGT1A1*28 allele was associated
with a 1.84-fold increased risk of developing severe neu-
tropenia (P 5 0.045). Both the UGT1A6 c.181A allele (OR 5
2.32; 95% confidence interval 1.03–3.30; P 5 0.045) and the
UGT1A7 c.208C allele (OR 5 2.00 95% confidence interval
1.12–3.58; P 5 0.025) were significant predictors of severe
neutropenia.
Upon multivariate analyses, no SNPs located in the
UGT1A1 first exon or its promoter region, including the
UGT1A1*28 (seven TA repeats) and the UGT1A1 c.-3156A
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alleles, remained significant in the Canadian patients. How-
ever, three markers situated in the central region of UGT1A
were associated with a 2-fold increased risk of neutropenia
grade 3–4 (Table 3), and are located in the UGT1A9 promoter
at position 2688 (MAF of 0.025), in the UGT1A7 first exon
(p.W208R; MAF of 0.412), and in the UGT1A6 first exon
(p.T181A; MAF of 0.352). Thus, in a second series of haplotype
analysis, we tested these three SNPs with the 39UTR SNP and
revealed a protective HI (OR 5 0.50; P 5 0.048) and two risk
haplotypes, HII and HIII, characterized by the presence of
2 (OR 5 2.18; P 5 0.014) and 3 (OR 5 5.28; P 5 0.030) un-
favorable alleles, respectively, revealing a dosage effect
(Fig. 2). This combination has not been tested in the Italian pop-
ulation due to a missing genotype for position 2688 of UGT1A9.
Discussion
Irinotecan combination chemotherapy causes severe and
unpredictable hematologic and GI toxicities in a substantial
percentage of patients (Negoro et al., 1991; Rothenberg et al.,
1993, 2001; Rougier et al., 1998; Saltz et al., 2000; Vanhoefer
et al., 2001; Fuchs et al., 2003). Despite several published
studies on genetic markers that help predict irinotecan-
associated severe neutropenia [reviewed in Hoskins et al.
(2007)], much work is still required to optimize individualized
treatment. Hence, better molecular markers to identify
patients at risk for complications, including severe diarrhea,
as well as to predict clinical response would be helpful to
patients andmedical oncologists. Currently, pharmacogenetic
data suggest that the UGT1A1*28/*28 genotype confers the
highest risk of severe neutropenia due to increased exposure
to SN-38 (Ando et al., 2000; Iyer et al., 2002; Innocenti et al.,
2004; Marcuello et al., 2004; Mathijssen et al., 2004; Rouits
et al., 2004; de Jong et al., 2006; Massacesi et al., 2006;
McLeod et al., 2006; Pillot et al., 2006; Toffoli et al., 2006; Cote
et al., 2007; Hoskins et al., 2007; Kweekel et al., 2008; Ruzzo
et al., 2008; Glimelius et al., 2011). Our current study
confirms that this genotype is associated with an increased
risk of severe neutropenia but in univariate analyses only,
whereas a more comprehensive analysis of variations at the
UGT1A locus suggests that other markers in the central
region of the gene and in the 39UTR region might better
predict this toxicity.
As previously reported, polymorphisms at theUGT1A locus
exhibit strong LD (Kohle et al., 2003; Peters et al., 2003;
Menard et al., 2009). There has been sporadic conflicting
information on the role of functional variants in the UGT1A1
promoter and coding regions and otherUGT1A genes involved
in irinotecan metabolism (Schulz et al., 2009). However,
considering that UGT1A1*28 is a well-accepted predictor of
severe neutropenia, and that strong LD is observed between
several functional genetic variations at the UGT1A locus in
diverse populations, it is thus not surprising to find an
association between severe neutropenia and other common
deleterious variations in UGT1A genes encoding SN-38–
metabolizing enzymes (Table 2) (Iyer et al., 1998; Ciotti et al.,
1999; Hanioka et al., 2001; Gagne et al., 2002).
Several UGT1A variations were individually associated
with severe neutropenia, and their presence is inferred in the
haplotype HII defined by a 5-marker haplotype acrossUGT1A
first exons previously reported by Cecchin et al. (2009), and
include the UGT1A1*28 allele (Fig. 2). We further described
a protective UGT1A haplotype allele (HIa) defined by the
reference sequence for these 5 markers, but also a variation in
the 39UTR region of the UGT1A gene common to all UGT1A-
derived enzymes. Individuals with this haplotype have less
chance of experiencing severe neutropenia (by 2-fold), and
therefore could potentially tolerate irinotecan with less
hematologic toxicity. Indeed, it has also been hypothesized
that higher irinotecan doses can be safely administered to
patients homozygous for the reference genotype UGT1A1*1/*1
owing to their relatively good tolerance of this drug (Schulz
et al., 2009). Only the UGT1A HIa haplotype was associated
with a reduced incidence of neutropenia, indicating that
the simple exclusion of patients with the UGT1A1*28/*28
genotype may be insufficient to predict good tolerance to
irinotecan with respect to severe neutropenia. Instead of
identifying a risk haplotype and inferring that UGT1A1*28
noncarriers would be protected from severe neutropenia, the
assessment of haplotype HIa seems to better identify those
who have a low risk of irinotecan-induced neutropenia,
presumably owing to the high glucuronidation activity of this
Fig. 1. Schematic representation of UGT1A and the haplotype analyses
associated with severe neutropenia based on previously investigated
markers. Variations are represented by squares: a yellow square re-
presents a reference nucleotide, whereas a green square represents
a variant (relative to the AF297093 sequence). Only haplotypes with an
MAF . 5% in the present study are shown. aBased on markers studied by
Cecchin et al. (2009). CI95%, 95% confidence interval; Freq., frequency.
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allele. Indeed, this haplotype, as well as the haplotype HIb
but with variation in the 39UTR, contains UGT1A1*1, the
reference UGT1A6/1A7, and UGT1A9, all of which are
associated with high UGT expression and glucuronidation
activity. These functional alleles may act synergistically to
enhance SN-38 conjugation in the liver and extrahepatic
tissues. It is thus tempting to speculate that genetic var-
iations at the 39 end affect gene expression. More studies are
definitely needed to confirm these findings and elucidate the
exact molecular mechanisms underlying our observation, and
to assess the functionality of 39UTR variations in UGT1A.
Additional analyses reveal that other variants in the
central region of the UGT1A gene, namely, those located in
UGT1A9 and in exons UGT1A7 and UGT1A6, are significant
predictors of severe neutropenia with at least a 2-fold
increased risk in multivariate analyses. Some of these SNPs
are only partially linked to the UGT1A1*28 allele (r2 values
between 0.028 and 0.82). Haplotype analyses with these
markers and the 39UTR variation, for a total of 4 markers
located in UGT1A9, UGT1A7, UGT1A6, and 39UTR, define
four common haplotypes, of which one is protective and is
referred to as HI5 ATA (OR5 0.50) and two, HII5 ACG and
HIII 5 CCG, that are linked to a significantly higher risk of
severe neutropenia. We further reveal a dosage effect with
a higher risk in patients carrying 2 markers and the highest
risk in those with 3 markers, also carrying the reference
39UTR allele that does not confer protection. This set of
UGT1A markers seems to improve risk prediction for severe
neutropenia. Previous in vitro reports support the contribu-
tion of UGT1A9, UGT1A7, and UGT1A6 enzymes in the
conjugation of SN-38 (Ciotti et al., 1999). Despite the un-
certainty of the extent of the contribution of these other
enzymes to SN-38 inactivation, several studies have found an
association between the UGT1A7*3 allele (p.W208R) and
irinotecan-induced toxicities (Ando et al., 2002; Carlini et al.,
2005; Lankisch et al., 2008). UGT1A7 is one of the ex-
trahepatic enzymes expressed mainly in the upper GI tract,
whereas both UGT1A6 and UGT1A9 are expressed in the
liver and other tissues (Nakamura et al., 2008). TheseUGT1A
variations and the identified set ofUGT1Amarkers should be
carefully evaluated in future studies of irinotecan toxicity.
The limitations of the study are its exploratory nature; the
limited sample size, particularly for haplotype analyses; and
the population studied that might be relatively genetically
homogeneous. Other limitations are related to a focus on specific
SNPs within the UGT1A gene, the scarcity of functional data
for some of the positive markers, and a need for validation and
study of additional cohorts.
TABLE 2
Polymorphisms in the UGT1A gene positively associated with severe neutropenia under allelic or genotypic analyses
Odds ratios (OR) have been calculated under the following models as specified: Dominant (a), recessive (b).
Gene Variation Alleles Neutropenia OR (95% CI) P Genotypes Neutropenia OR (95% CI) P Na
0–2 3–4 0–2 3–4
UGT1A9 c.-1212 G 189 29 2.12 (1.17–3.84) GG 71 8 3.24b (1.32–7.98) 0.010 160
A 77 25 0.016 GA 47 13
AA 15 6
c.-688 A 264 50 5.28 (1.28–21.81) AA 130 23 5.65b (1.32–24.22) 0.028 161
C 4 4 0.030 AC 4 4
CC 0 0
c.-440 C 182 29 1.97 (1.10–3.53) CC 65 8 2.36b (0.97–5.72) 0.062 162
T 86 27 0.030 CT 52 13
TT 17 7
UGT1A7 p.W208R T 168 25 2.00 (1.12–3.58) TT 53 6 2.59c (1.03–6.51) 0.057 164
C 104 31 0.025 TC 62 13
CC 21 9
UGT1A6 p.S7A T 160 24 2.00 (1.12–3.57) TT 53 6 2.59c (1.03–6.51) 0.057 164
G 110 33 0.019 TG 62 13
GG 21 9
p.T181A A 186 27 2.32 (1.30–4.16) AA 66 8 3.55c (1.38–9.18) 0.017 164
G 86 29 0.005 AG 54 11
GG 16 9
p.R184S A 180 26 2.26 (1.26–4.04) AA 62 8 3.64c (1.45–9.13) 0.010 164
C 92 30 0.006 AC 56 10
CC 18 10
UGT1A1 c.-3156 G 193 29 2.28 (1.27–4.09) GG 73 9 3.00c (1.14–7.93) 0.036 164
A 79 27 0.007 GA 47 11
AA 16 8
c.-54_-53 6 185 30 1.84 (1.03–3.30) 66 66 9 2.33c (0.86–6.31) 0.137 164
7 87 26 0.045 67 53 12
77 17 7
95% CI, 95% confidence interval.




Stepwise logistic regression model for severe neutropenia
Variables entered in the first step: UGT1A9 c.-1212, UGT1A9 c.-688, UGT1A9 c.-440,
UGT1A7 p.W208R, UGT1A6 p.S7A, UGT1A6 p.T181A, UGT1A6 p.R184S,
UGT1A1 c.-3156, UGT1A1 c.-54_53insTA. Age and treatment type were also
included in the model.
Severe Neutropenia Estimate S.E. OR (95% CI) P
UGT1A6 p.T181A 0.741 0.317 2.10 (1.13–3.91) 0.020
UGT1A7 p.W208R 0.701 0.311 2.00 (1.12–3.57) 0.024
UGT1A9 c.-688 1.509 0.810 4.52 (0.92–22.15) 0.063
95% CI, 95% confidence interval; OR, odds ratio.
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In conclusion, the ultimate objective of pharmacogenetic
studies is to develop tests that can be used to identify patients
more likely to respond to a particular therapy and individuals
who are more liable to suffer adverse reactions. In our study,
we characterize UGT1A haplotypes that could potentially
lead to more robust predictive tests. Additional studies that
include a more comprehensive assessment of variations in
UGT1A, including variations in the 39UTR region and those
across the locus, are warranted in irinotecan-containing
dosage regimens, and may help clarify the role of UGT1A in
the management of irinotecan toxicity and response.
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